[
  {
    "ts": null,
    "headline": "Biogen Inc. stock underperforms Monday when compared to competitors",
    "summary": "Biogen Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=009e295684f4ce49c655f27660133cf1ae0efa93a5c0b6f889ba43ca4a744279",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757956080,
      "headline": "Biogen Inc. stock underperforms Monday when compared to competitors",
      "id": 136813293,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=009e295684f4ce49c655f27660133cf1ae0efa93a5c0b6f889ba43ca4a744279"
    }
  },
  {
    "ts": null,
    "headline": "H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best defensive stocks to buy, according to Steve Cohen. On September 5, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $194 price target. The positive stance echoes the research firm’s confidence about the company’s promising lupus franchise. According to H.C. Wainwright, the lupus treatments litifilimab […]",
    "url": "https://finnhub.io/api/news?id=b98f63cc25b07f6fce0a073e8c8e7e304bd529e500f1cebeff7e0d86352d6266",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757945009,
      "headline": "H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects",
      "id": 136749892,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best defensive stocks to buy, according to Steve Cohen. On September 5, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $194 price target. The positive stance echoes the research firm’s confidence about the company’s promising lupus franchise. According to H.C. Wainwright, the lupus treatments litifilimab […]",
      "url": "https://finnhub.io/api/news?id=b98f63cc25b07f6fce0a073e8c8e7e304bd529e500f1cebeff7e0d86352d6266"
    }
  }
]